Technical Analysis for COCP - Cocrystal Pharma, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Golden Cross | Bullish | 0.00% | |
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Wide Bands | Range Expansion | 2.33% | |
Calm After Storm | Range Contraction | 6.80% | |
Wide Bands | Range Expansion | 6.80% | |
Gapped Down | Weakness | 6.80% | |
Calm After Storm | Range Contraction | 6.80% | |
Wide Bands | Range Expansion | 6.80% |
Alert | Time |
---|---|
Possible NR7 | about 14 hours ago |
Possible Inside Day | about 14 hours ago |
Up 2% | about 15 hours ago |
Up 1% | about 15 hours ago |
60 Minute Opening Range Breakout | about 15 hours ago |
Get a Trading Assistant
- Earnings date: 11/11/2024
Cocrystal Pharma, Inc. Description
Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HCV. Phase 1b studies in HCV infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 4 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 60% of the Company, including the Frost Group. OPKO Health, Inc., Brace Pharma Capital, LLC and Teva Pharmaceuticals Industries, Ltd. are corporate investors.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biology Coronavirus Influenza Viruses Microbiology Virus Antiviral Drug Biocides HCV Influenza Viruses Opko Health Pharmaceuticals Industries
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 3.1 |
52 Week Low | 1.325 |
Average Volume | 19,985 |
200-Day Moving Average | 1.86 |
50-Day Moving Average | 1.86 |
20-Day Moving Average | 1.90 |
10-Day Moving Average | 2.02 |
Average True Range | 0.18 |
RSI (14) | 64.54 |
ADX | 32.56 |
+DI | 30.29 |
-DI | 12.31 |
Chandelier Exit (Long, 3 ATRs) | 1.91 |
Chandelier Exit (Short, 3 ATRs) | 2.19 |
Upper Bollinger Bands | 2.25 |
Lower Bollinger Band | 1.56 |
Percent B (%b) | 0.93 |
BandWidth | 36.25 |
MACD Line | 0.08 |
MACD Signal Line | 0.04 |
MACD Histogram | 0.0368 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.41 | ||||
Resistance 3 (R3) | 2.39 | 2.29 | 2.38 | ||
Resistance 2 (R2) | 2.29 | 2.24 | 2.31 | 2.36 | |
Resistance 1 (R1) | 2.25 | 2.21 | 2.27 | 2.27 | 2.35 |
Pivot Point | 2.15 | 2.15 | 2.17 | 2.17 | 2.15 |
Support 1 (S1) | 2.11 | 2.10 | 2.13 | 2.13 | 2.05 |
Support 2 (S2) | 2.01 | 2.07 | 2.03 | 2.04 | |
Support 3 (S3) | 1.97 | 2.01 | 2.03 | ||
Support 4 (S4) | 1.99 |